

PROJECT SUMMARY/SAMPLE SUBMISSION FORM*

ITSIBIO #:_____(FOR INTERNAL USE)

CONFIDENTIAL & PRIVILEGED INFORMATION**

| PRIMARY CONTACT (PC)/PRINCIPAL INVESTIGATOR (PI): | | | SECONDARY CONTACT INFORMATION: | |
|--|--|--|--|--|
| Name: | | | Name: | |
| | | | Email: | |
| Address: | | | Phone: | |
| | | | Fax: | |
| | | | | |
| | | | BILLING INFORMATION (IF DIFFERENT FROM PC/PI): | |
| | | | Name: | |
| | | | Address: | |
| Email: | | | | |
| Phone: Fax: | | | | |
| rdX. | | | Email: | |
| | | <u> </u> | Phone/Fax: | |
| 1. PROJECT TITLE: | | | | |
| 2. PROJECT S | LINANAADV | | | |
| (To help us t | | | | |
| your project g | goals and be | | | |
| able to help y | | | | |
| please include the objective of the study, and | | | | |
| ultimate go | | | | |
| Targeted genomics and proteomics please also list | | | | |
| the gene/protein accession | | | | |
| numbers. <u>PLE</u> <u>EXCEED TH</u> | | | | |
| PROVI | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| INSTRUCTIONS: SELECT THE APPROPRIATE BOX TO INDICATE YOUR CHOICE. A SELECTED BOX MEANS "YES" & A BOX LEFT BLANK MEANS "NO" | | | | |
| 3. ANALYTICAL PROTEOMICS (Qualitative/Quantitative): | | | | |
| SERVICE(S) R | EQUIRED | LC/MS/MS iTRAQ TMT Label Free Quantitation 2D-DIGE 2D-DIGE–MS MudPIT | | |
| | | Host Cell Protein Analysis Rob | otic Spot Picking Robotic In-Gel Digestion Other: | |
| | POST TRANSLATIONAL MODIFICATION MAPPING: | | | |
| | | Acetylation Glycosylation Phosphorylation Ubiquitination Other: | | |
| | | DNA ANALYSIS/GENOMICS | | |
| | | Paternity test Human identific | ation Gene expression analysis | |
| | | OTHER SERVICES: | | |
| | | 2D-Western Protein Purity Ass | essment Luminex-xMAP Affymetrix/Panomic-QuantiGene | |
| | | Agriciit biodilalyzeiOttleft | | |

| FAST, ACCURATE, EASY-TO-USE | PROJECT SUMMARY/SAMPLE SUBMISSION FORM* ITSIBIO #:(FOR INTERNAL USE) | | | |
|--|--|--|--|--|
| 4. SOURCE OF SAMPLE | HUMAN RAT MOUSE RABBIT PLANT OTHER (EXPLAIN) | | | |
| 5. SAMPLE TYPE | SERUM PLASMA TISSUE CELL PELLET HPLC FRACTION | | | |
| | GEL PLUG/GEL BAND COOMASSIE STAINED SILVER STAINED | | | |
| | MEMBRANE SECTION OTHER (EXPLAIN): | | | |
| 6.PRESENCE OF TOXIC | SAMPLE CONTAINS TOXIC AGENT SAMPLE CONTAINS INFECTIOUS AGENT | | | |
| OR INFECTIOUS AGENT | NO YES (EXPLAIN BELOW) NO YES (EXPLAIN BELOW) | | | |
| 7. EXPECTED SAMPLE SUBMISSION DATE | 8. # OF SAMPLES: | | | |
| 9. ANY OTHER | | | | |
| INFORMATION | | | | |
| | | | | |
| 10. PERSON | NAME SIGN: DATE: | | | |
| COMPLETING FORM | NAIVIE SIGN. | | | |
| 11. How DID YOU HEAR ABOUT US? Search Engine Email Advertisement Contacted by ITSIBIO Colleag | | | | |
| | ITSIBIO Newsletter Flyer at a Conference Other (Explain): | | | |
| NOTE: | | | | |
| 1. YOU ARE UNDER NO OBLIGATION TO CARRYOUT OUT THE PROJECT BY COMPLETING THIS FORM. | | | | |
| COMPLETE ALL SECTIONS, SIGN AND RETURN BY EMAIL OR FAX. THE INFORMATION PROVIDED WILL BE USED TO DEVELOP AN INITIAL PROJECT PROPOSAL (IPP) WHICH DESC | | | | |
| | WORK, TIME LINE AND BUDGET. | | | |
| 4. SAMPLES MAY NOT BE SHIPPED UNTIL THE IPP HAS BEEN RECEIVED, ACCEPTED AND SIGNED. DESCRIBE TOXIC AGENT: | | | | |
| | | | | |
| | | | | |
| | | | | |
| DESCRIBE INFECTIOUS AG | <u>SENT:</u> | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| *+++++++++++++++++++++++++++++++++++++ | | | | |
| rose. The Project Juninary, Jampie Juninssion Form will enable History, 17 fully understand the project diff, objective and | | | | |

Please return the completed form by Email to project2@itsibio.com or Fax it to +1-814-262-7334.

^{*}PURPOSE: The Project Summary/Sample Submission Form will enable ITSIBIO; 1) fully understand the project aim, objective and goals, 2) prepare a proposal that describes the proposed method/technology that will be used, 3) estimate timeline and 4) estimate the budget.

^{**}CONFIDENTIAL INFORMATION: Although all information submitted to ITSIBIO is automatically protected by Company's Confidential and Non-Disclosure Policy, we recommend that you do not include confidential information at this stage unless a formal Confidential & Non Disclosure Agreement has been signed.